Physician profile
Mark Bilella
NPI 1447200803
$11,309.22
in general payments reported to CMS, 2019-2025
51 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $1,232 · 2021: $1,627 · 2022: $1,529 · 2023: $2,087 · 2024: $1,882 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,055.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,645.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,447.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,295.07 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $788.56 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $779.85 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $654.15 | 2019-2025 | |
| Pfizer INC. | $513.63 | 2019-2025 | |
| Corium, LLC | $375.89 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $368.83 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $359.11 | 2019-2025 | Vpriv |
| Glaxosmithkline, LLC. | $303.55 | 2021-2025 | Bexsero, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $299.15 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Dexcom, INC. | $249.70 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $187.78 | 2020-2021 | |
| Abbott Laboratories | $178.26 | 2022-2025 | Freestyle Libre 3 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bilella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.